Artelo Biosciences, Inc.(ARTL)Earnings, Financials & Key Ratios

ARTL•NASDAQ

$1.12

Price updated Jun 27, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryNeuroscience and Psychiatry Therapies

AboutArtelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Show more

Revenue$0
EBITDA-$11M-11.4%
Net Income-$13M-31.1%
EPS (Diluted)-5.47-438.1%
ROE-1625.11%-1108.1%

ARTL Price & Volume

Artelo Biosciences, Inc. (ARTL) stock price & volume — 10-year historical chart

Loading chart...

Persistent Clinical Burn Risks Future Operational Continuity

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity and dilution

Key Thesis Takeaways

Artelo Biosciences remains a pre-revenue biotechnology firm entirely dependent on external capital to sustain its clinical development pipeline.
The company faces significant structural risks, evidenced by a cumulative deficit of $63.0 million as of 2025Q4 and a history of recurring net losses, most recently $3.0 million in 2026Q1.
Investors should monitor the firm's ability to manage its $755,000 debt load against a volatile cash position, as the current trajectory suggests continued reliance on dilutive financing to maintain operations.

Verdict Logic

the company's precarious liquidity, evidenced by a cash balance of only $600,000 against quarterly operating losses often exceeding $2.5 million, presents an imminent risk of further shareholder dilution.

ARTL Growth Metrics

Artelo Biosciences, Inc. (ARTL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-38.6%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-214.08%

Return on Capital

10 Years-715.23%

5 Years-343%

3 Years-518.88%

Last Year-1355.2%

Peers Comparison

Key metrics vs top competitors for Artelo Biosciences, Inc. (ARTL)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
ARTLArtelo Biosciences, Inc.Current	$1.12	$2.61M	-0.20	—	—	-1625.11%	—
INABIN8bio, Inc.	$1.36	$6.3M	-0.31	—	—	-96.39%	—
OWLTOwlet, Inc.	$5.49	$19.95M	-2.45	35.43%	-43%	—	—
AEYEAudioEye, Inc.	$5.59	$69.84M	-22.36	14.52%	-9.05%	-70.95%	—
TPVGTriplePoint Venture Growth BDC Corp.	$4.70	$190.82M	3.85	36.55%	-19.55%	-3.39%	—
IIPRInnovative Industrial Properties, Inc.	$62.93	$1.8B	16.01	-13.8%	45.58%	6.41%	—